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MONOTHERAPY OF ANDROGEN DEPRIVATION THERAPY VERSUS RADICAL
PROSTATECTOMY AMONG VETERANS WITH LOCALIZED PROSTATE CANCER: A
COMPARATIVE EFFECTIVENESS ANALYSIS OF RETROSPECTIVE COHORTS
Liu J, Shi L, Sartor O
Tulane University, New Orleans, LA, USA
OBJECTIVES: There is no consensus regarding the optimal treatment for localized
prostate cancer. This study aimed to examine the comparative effectiveness of
monotherapy of either primary androgen deprivation therapy (PADT) or radical
prostatectomy (RP) in terms of overall survival rate.METHODS:Male patients with
localized prostate cancer were identified in the Veterans Affairs Veterans Inte-
grated Service Network 16 data warehouse (January, 2003-June, 2006), with one
year baseline and at least 3-year follow-up (till 06/2009). Eligible patients (18-75
years old) had no other cancer history and used PADT ormonotherapy of RPwithin
6 months after the first diagnosis of prostate cancer. The overall survival from
initiation of index treatment was analyzed using Kaplan-Meier method and Cox
proportional hazard regression, adjusted for age, race, marital status, insurance
type, cancer stage, Charlson comorbidity index, alcohol and tobacco use. RESULTS:
The age was 66.2(6.07) [Mean(SD)] years in 211 PADT patients, 59.9(6.15) in 215 RP
patients. During the follow-up of 4.2(0.95) years, the cumulative incidence of death
was 29 (13.74%) among PADT patients and 6 (2.79%) among RP patients (p0.001).
The overall 3-year survival rate was 89.57% in PADT and 98.60% in RP (p0.001).
Patients who received PADT had almost 4 times as high mortality risk as those
using RP (HR 3.820, 95% CI1.483 to 9.845, p0.006). CONCLUSIONS: Overall sur-
vival rate following RP among localized prostate cancer patients was significantly
higher than that after PADT, controlling for other covariates. More research among
a larger population with longer follow-up are warranted to confirm this finding.
CN2
ESTIMATED EFFECTS OF THE NATIONAL BREAST AND CERVICAL CANCER
EARLY DETECTION PROGRAM ON CERVICAL CANCER MORTALITY
Ekwueme DU1, Uzunangelov V2, Hoerger T2, Saraiya M1, Miller J1, Hall I1, Benard V1,
Royalty J1, Li C1
1Centers for Disease Control and Prevention, Atlanta, GA, USA, 2RTI International, Research
Triangle Park, NC, USA
OBJECTIVES: The National Breast and Cervical Cancer Early Detection Program (NB-
CCEDP) is the largest organized cancer screening program for low-income, un-insured
and under-insured women in the United States. The program’s effectiveness in in-
creasing the life expectancy of participating women has never been measured. We
estimated the benefits of NBCCEDP-funded cervical cancer screening (Program) in
terms of life-years (LYs) saved compared to No Program and No Screening scenarios.
METHODS: Based on an existing model developed by Myers et al., we constructed a
cervical cancer simulationmodel bymodifying the age and screening schedule of the
cohort to reflect screening frequency for NBCCEDP participants from 1991-2007. We
estimated screening habits in the absence of the program based on data from the
1990-2005 National Health Interview Survey. We performed Markov cohort analysis
for each age in the 18-64 range and calculated an overall weighted average using the
age distribution at first NBCCEDP Pap test for screening.Weighted averages were pro-
duced for three scenarios –women receiving testing from theNBCCEDP (the Program),
women receiving testing from alternative sources in the absence of the program (No
Program), and women receiving no testing at all (No Screening). We compared LY
estimates for 69,100womendetectedwith humanpapillomavirus infection, low-and-
high-grade squamous intraepithelial lesions or cervical cancer under the program to
the counterfactual of having their disease undetected under No Program and No
Screening scenarios. RESULTS: From 1991-2007, we estimate that the Program added
10,369 LYs to the total lifespan of tested women when compared to No Program, and
101,509 LYswhen compared toNoScreening. Furthermore, the Programprevented an
estimated 325 cervical cancer deaths relative to No Program, and 3,825 relative to No
Screening. CONCLUSIONS: These estimates suggest that NBCCEDP cervical cancer
screening may have reduced mortality among medically underserved women in
the United States.
CN3
THE VALUE OF RESEARCH FOR ERCC1 TESTING IN STAGE I NON-SMALL CELL
LUNG CANCER
Roth J1, Carlson JJ2, Steuten L3, Veenstra D1
1University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA,
USA, 2University of Washington, Seattle, WA, USA, 3University of Twente, Enschede, The
Netherlands
OBJECTIVES: To assess the value of additional research for ERCC1 expression test-
ing to guide adjuvant chemotherapy decisions in fully resected Stage I non-small
cell lung cancer (NSCLC).METHODS:We refined a previously-developed decision-
analytic model to estimate the expected value of perfect information (EVPI) and
expected value of sample information (EVSI) for two treatment strategies: 1) ERCC1
testing to inform adjuvant chemotherapy decisions, with ERCC1 patients receiv-
ing no chemotherapy and ERCC1- patients receiving chemotherapy; 2) standard
care, with all patients receiving no chemotherapy. Model parameters and uncer-
tainty ranges were derived from a retrospective analysis of the International Ad-
juvant Lung Cancer Trial, published literature, and government sources. The af-
fected population was derived from SEER incidence estimates, and examined over
a discounted 10-year time horizon. RESULTS: At a willingness-to-pay of $150,000
per quality-adjusted life year, ERCC1 and standard care strategies resulted in av-
erage net-benefits of $630,500 and $625,200, respectively. The ERCC1 and standard
care strategies produced greater net-benefit in 64% and 36% of 10,000 simulations,
respectively. The average net-benefit difference was $14,000 in simulations where
the standard care strategy was optimal. With an affected population of 233,825;
EVPI was $1.2 billion. Preliminary estimates suggest an EVSI of approximately $20
million at plausible sample sizes. CONCLUSIONS: Considerable value could be
realized through additional research to reduce uncertainty about the comparative
health outcomes of ERCC1 and standard care strategies. The EVPI of $1.2 billionwas
driven by the large 10-year affected population, probability that ERCC1 testing is
not the optimal strategy, and consequences of selecting the non-optimal strategy.
Forthcoming results will enable estimation of the expected net-benefit of sam-
pling, which compares the EVSI of various study designs and sample sizes to the
cost of conducting such studies. These findings can assist stakeholders in priori-
tizing funding for ERCC1 research relative to alternative research investments.
CN4
PALONOSETRON VERSUS OTHER 5-HYDROXYTRYPTAMINE3 RECEPTOR
ANTAGONISTS FOR PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND
VOMITING AMONG MEDICARE PATIENTS WITH CANCER
Craver C1, Gayle J1, Balu S2, Buchner D2
1Premier, Inc., Charlotte, NC, USA, 2Eisai, Inc., Woodcliff Lake, NJ, USA
OBJECTIVES: To assess the rate of uncontrolled chemotherapy induced nausea and
vomiting (CINV) associated with palonosetron initiation versus other 5-hydroxy
tryptamine3-receptor antagonists (5-HT3-RAs) among Medicare patients with cancer
on chemotherapy (CT) treatment in a hospital outpatient setting. METHODS: Medi-
care patients with a cancer diagnosis initiating CT and anti-emetic prophylaxis with
palonosetron (Group 1) and other 5-HT3-RAs (Group 2) for the first time (index date)
between April 1, 2007 – March 31, 2009 were identified from the Premier Perspective
database. Inclusion criteria were no evidence of nausea and vomiting, CT, and anti-
emetic medication in the 6-month pre-index date period and 36-consecutivemonths
of data submission. A negative binomial distribution generalized linear multivariate
regression model estimating the rate of CINV events on CT emetogenicity and cycle
matched groups in the follow-up period (first of eight CT cycles or six months post-
index date) was developed after adjusting for several demographic and clinical
variables. RESULTS: Of 4799 identified patients, 962 initiated palonosetron (Group 1;
20.1%). Group 1 patients were significantly younger [70.4 (SD: 9.3) versus 71.6 (9.0)
years; p0.0001], comprisedmore females [52.9%versus 48.6%; p0.0001], lessAfrican
Americans [8.7% vs. 11.3%] and more Hispanic patients [6.3% versus 2.5%]; all
p0.0001,more highly andmoderately emetogenic CT [33.6% versus 20.7% and; 47.3%
versus 40.3%, respectively; p0.0001], and more lung and breast [30.9% vs. 24.9% and
12.3% vs. 9.6%, respectively; p0.0001]. In the follow-up period, the regression model
predicted a 11.8%decrease in theCINVevents per CT cycle for Group 1 patients versus
Group 2 patients; p0.05. CONCLUSIONS: In this retrospective hospital outpatient
study, aftermatching for CT emetogenicity and cycle and adjusting for other potential
confounders, Medicare patients with cancer initiated on palonosetron were more
likely to experience a significantly lower rate of CINV events per CT cycle versus those
initiating other 5-HT3-RAs.
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OBJECTIVES: To evaluate effects of dose escalation on clinical outcomes of RA
patients initiating TNF-blocker treatments in community practice. METHODS:
TNF-blocker-naïve adult RA patients initiating etanercept, adalimumab, or inflix-
imab (index) between July 1, 2005 and May 31, 2008 with 12 months’ enrollment
post-index were identified from the Ingenix database. Patients receiving 9
months TNF-blocker treatment or diagnosed with psoriasis, psoriatic arthritis, an-
kylosing spondylitis, or Crohn’s disease were excluded. Rates of dose escalation
using 3 different methods were calculated using claims data. Participating physi-
cians provided de-identified charts. Each chart was reviewed by 4–6 clinical rheu-
matologists to evaluate and agree on overall clinical change from baseline to the
visit closest to 1 year post-index (123 months). Multivariate models compared
change in clinical outcomes and dose escalation rates, controlling for differences
among etanercept, adalimumab, and infliximab patients at index. RESULTS: Over-
all, 715 etanercept, 501 adalimumab, and 393 infliximab patients were identified
from claims; 141 etanercept, 115 adalimumab, and 104 infliximab patients had
evaluable charts. Patient characteristicswere similar among the claims and charts.
Regardless of dose escalation method used, significantly fewer etanercept-treated
patients had dose escalations (1.8%, 5.2%, 6.7%) than patients treated with adali-
mumab (9.8%, 8.6%, 10.4% respectively) or infliximab (50%, 31%, 34% respectively)
(p0.05 for all comparisons). After treatment initiation, 86% of etanercept-treated
patients had “much better” or “better” clinical outcomes at 123 months, versus
82% of adalimumab patients and 78% of infliximab patients. Multivariate analyses
showed significantly fewer dose escalations in etanercept patients (p0.05), with
no significant difference in clinical change score between etanercept patients and
adalimumab (p0.22) or infliximab (p0.07) patients. CONCLUSIONS: This study
showed dose escalation in fewer etanercept than adalimumab or infliximab patients,
but similar improvements in clinical outcomes for all 3 treatments, indicating that
higher dose escalation rates may not be associated with better clinical outcomes.
CO2
REAL-WORLD COST-EFFECTIVENESS ANALYSIS OF CANCER DRUGS:
COMPARATIVE EFFECTIVENESS RESEARCH USING RETROSPECTIVE CANADIAN
REGISTRY DATA BEFORE AND AFTER DRUG APPROVAL
Khor S1, Krahn M2, Hodgson D3, Bremner K4, Luo J5, Hoch J1
1Cancer Care Ontario, Toronto, ON, Canada, 2Toronto Health Economics and Technology
Assessment (THETA) Collaborative, Toronto, ON, Canada, 3Princess Margaret Hospital, Toronto,
ON, Canada, 4University Health Network, Toronto, ON, Canada, 5The Institute for Clinical
Evaluative Sciences, Toronto, ON, Canada
OBJECTIVES: Using linked administrative databases from Ontario, our study exam-
ined the “realworld” cost, effectivenessandcost-effectivenessofRituximab indiffuse-
large-B-cell lymphoma.METHODS: Patientswere defined as thosewhohad a diagno-
sis of diffuse-large-B-cell lymphoma according to ICD-O histology classification
between January 1997 and December 2007 and received either CHOP (cyclophospha-
mide, doxorubicin, vincristine and prednisone) or R-CHOP (CHOP plus Rituximab) as
first line treatment.Weusedahistorical cohort design to compare theoverall survival,
toxicity profiles, direct costs, and cost-effectiveness of CHOP before Rituximab was
approved (pre-era CHOP) with R-CHOP after Rituximab approval (post-era RCHOP).
R-CHOP and CHOP patients were hard-matched on age, and then subsequently
matched on propensity scores by use of a 1:1 matching algorithm. Propensity scores
were calculated from demographic and clinical history information. We estimated
resourceuse anddirectmedical costs using the linkedadministrativedata. To analyze
censored cost data, we employed and compared different methods, including the
simple non-adjusted average, the Kaplan-Meier sample average estimator, inverse
probability weighting estimator, Pfeifer and Bang’s estimator (2005) and Basu’s two-
part estimator (2010). RESULTS: A total of 1131 matched pairs of patients were eval-
uated. 3-year overall survivalwas significantly improved in the post-era RCHOP group
compared to pre-era CHOP (69% [95%CI 66-71] vs 59% [95%CI 56-62]; Klein test
p0.001). Groups did not differ in the frequency of adverse events, but 3-year direct
cost was significantly higher in the post-era RCHOP group. The incremental cost-
effectiveness ratio varied depending on the method employed. CONCLUSIONS: This
study illustrated how different methods can be applied to observational data to esti-
mate costs and cost-effectiveness. The results from this study can be compared to
those from clinical trials and economic models. This will help drug decision-makers
calibrate healthcare policies while helping researchers evaluate assumptions made
andmethods used in economic models.
CO3
PROJECT LIBRA: A NEW ANALYTIC TOOL FOR COMPARATIVE EFFECTIVENESS
ANALYSES OF MULTIPAYER CLAIMS DATABASES
Mark T1, Pepitone A2, Hatzmann M1, Navathe A3, Goodrich K3, Chang S1
1Thomson Reuters, Washington, DC, USA, 2Thomson Reuters, Santa Barbara, CA, USA,
3Assistant Secretary for Planning and Evaluation, Washington, DC, USA
OBJECTIVES: The project aimed to develop a secure, interactive tool to enable
researchers to perform comparative effectiveness studies and other types of re-
search on a multipayer claims database with reduced need for complicated
programming. METHODS: A common data model, through which multiple data
sources are standardized and linked via commondata structures and vocabularies,
was established. It was used to format five administrative databases: the Medicare
Chronic Condition Warehouse, the Thomson Reuters MarketScan® Medicaid Mul-
tistate, Medicare Supplemental, and Commercial databases, and the Healthcare
Cost and Utilization Project National Inpatient Sample database. A web-based Us-
er-Interface was developed that captures the logic typically required by CERmeth-
ods and capitalizes on the longitudinality of administrative data. Tools were de-
veloped to allow users to search taxonomies to select particular drugs, diagnoses,
or procedures by typing in substrings of the numeric codes or textual descriptions.
The tool allows researchers to apply enrollment and demographic constraints and
create variables. CER studies were conducted including a comparison of atrial fi-
brillation treatment with rate or rhythm control medications. RESULTS: The tool
allowed users to quickly define a study sample. Flow diagrams graphically illus-
trated the attrition of the sample size and visualization of treatment and outcomes.
Embedded SAS procedures enabled reporting and analysis of comparison popula-
tions. The analyses revealed a higher rate of coronary artery disease and heart
failure prior to drug initiation among the amiodorone versus the calcium channel
blocker population and a higher rate of post-drug initiation acquired hypothyroid-
ism, and pulmonary disease among the amiodorone versus the calcium channel
blocker population. CONCLUSIONS: New data designs and software analytic tools
may allow claims databases to bemore efficiently leveraged. The tool developed for
this project has the following advantages: 1) allows for a substantial portion of the
research exploration, hypothesis generation; and statistical analysis to be per-
formed in real-time using aweb-based interface; 2) improves the speed of research;
and 3) allows access to a multipayer database.
CO4
POTENTIAL COST SAVINGS FROM COMPARATIVE EFFECTIVENESS RESEARCH:
LESSONS FROM COURAGE STUDY
Bonakdar tehrani A, Howard D
Emory University, Atlanta, GA, USA
OBJECTIVES: During the debate over health reform, comparative effectiveness re-
search was touted as a relatively painless approach to reducing costs. A compara-
tive effectiveness study of two treatments will find either that the costlier treat-
ment is more effective or is not more effective than a less expensive alternative.
Studies that report negative results have the potential to reduce costs, but only if
findings affect clinical practice. One concern is that the same factors that promote
rapid adoption of new therapies in the U.S. may retard the abandonment of exist-
ing technologies found to be ineffective.METHODS: The COURAGE trial found that
optimalmedical therapy is as effective as percutaneous coronary intervention (PCI)
for patients with stable angina. PCI refers to stenting and angioplasty. The trial was
published and widely publicized in early 2007. We evaluate trends in PCI volume
pre- and post-COURAGE by indication using 1) 100% samples of outpatient and
inpatient discharge data for California, Florida, New Jersey, andMaryland, 2) a 100%
sample of discharge data for Veteran’s Administration hospitals and 3) data from a
proprietary cardiac catheterization laboratory registry at 15 hospitals. RESULTS:
Between the fourth quarter of 2006 and the fourth quarter of 2007, PCI volume in
California, Florida, New Jersey, and Maryland among patients without serious cor-
onary disease declined from approximately 17,000 to 13,000 procedures (an 18%
decline). There was only a 5% decline among patients with unstable angina, who
were not included in COURAGE. We found similar patterns in the other datasets.
CONCLUSIONS: Publication of the COURAGE trial had an impact on PCI volume.
Many patients with stable angina continue to receive PCI. The results are consis-
tent with the view that as long as the health system is configured around proce-
dural-based medicine, the impact of trials which find that medical therapy is as
effective as invasive procedures will be modest.
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DM1
IMPACT OF A PHARMACY REFILL MANAGEMENT SYSTEM ON OUTCOMES IN
END STAGE RENAL DISEASE (ESRD) PATIENTS
Rubin JL1, Wilson SM1, Golomb J2
1DaVita Clinical Research, Minneapolis, MN, USA, 2DaVita Rx, San Bruno, CA, USA
OBJECTIVES: In dialysis patients, bone and mineral (phosphorous, calcium) and
regulatory hormones (parathyroid hormone (PTH)) become dysregulated, increas-
ing risk of fractures, cardiac events and death. First line treatment is a low phos-
phorus diet and prescription phosphate binders.We examined the impact of a refill
management system (RMS) - which helps patients proactively manage their refills
using predictive algorithms and refill reminders for prescriptions - on serum phos-
phorus, calcium and PTH in patients prescribed phosphate binder monotherapy.
METHODS: Data from a large dialysis organization were used to identify dialysis
patients prescribed monotherapy phosphate binder between 1/1/2008-9/30/2010
with at least 6 months of follow-up. Patients enrolled in the RMS were 1:1 propen-
sity score matched to patients not enrolled utilizing age, race, gender, dialysis
vintage, body mass index, baseline laboratory values (albumin, calcium, Kt/V,
phosphorus, PTH, normalized protein catabolic rate), Charlson comorbidity score,
and other comorbid conditions commonly associated with ESRD. The matched
cohorts were compared on the percent meeting guideline ranges for phosphorus
(3.5-5.5 mg/dL), corrected calcium (8.4-9.5 mg/dL) and PTH (150-600 pg/mL). Values
were assessed over the 6-months following the first phosphate binder prescription.
Differences between groups were tested using chi-square for proportions.
RESULTS: 3,247 RMS patients met the inclusion criteria and were matched 1:1 to a
cohort of non-RMS patients. There were no significant differences between the
groups on any baseline variables. Patients enrolled in the RMS were more likely to
be in target range over the 6month period on all 3 measures: phosphorus (58.0% vs
55.1%); corrected calcium (74.3% vs. 69.1%) and PTH (80.5% vs. 77.2%), compared to
propensity matched controls. All differences were significant at the p0.05 level.
CONCLUSIONS: Results indicate that participation in a pharmacy RMS is associ-
ated better laboratory outcomes for dialysis patients.
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